33,953 Shares in Aurinia Pharmaceuticals Inc $AUPH Acquired by PSP Research LLC

PSP Research LLC purchased a new position in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 33,953 shares of the biotechnology company’s stock, valued at approximately $542,000. Aurinia Pharmaceuticals comprises about 0.5% of PSP Research LLC’s investment portfolio, making the stock its 19th largest holding.

Several other hedge funds have also added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Aurinia Pharmaceuticals by 25.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,407 shares of the biotechnology company’s stock worth $102,000 after purchasing an additional 1,318 shares during the last quarter. Concurrent Investment Advisors LLC lifted its holdings in Aurinia Pharmaceuticals by 7.8% during the 4th quarter. Concurrent Investment Advisors LLC now owns 30,270 shares of the biotechnology company’s stock worth $483,000 after purchasing an additional 2,200 shares during the last quarter. CWM LLC lifted its holdings in Aurinia Pharmaceuticals by 15.5% during the 4th quarter. CWM LLC now owns 16,543 shares of the biotechnology company’s stock worth $264,000 after purchasing an additional 2,225 shares during the last quarter. IFP Advisors Inc lifted its holdings in Aurinia Pharmaceuticals by 0.9% during the 3rd quarter. IFP Advisors Inc now owns 262,380 shares of the biotechnology company’s stock worth $2,910,000 after purchasing an additional 2,346 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Aurinia Pharmaceuticals by 24.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 14,252 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 2,834 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $15.55 on Wednesday. The stock has a market capitalization of $2.00 billion, a PE ratio of 7.17 and a beta of 1.44. The company has a debt-to-equity ratio of 0.08, a current ratio of 5.55 and a quick ratio of 5.01. The business has a fifty day moving average price of $15.33 and a two-hundred day moving average price of $15.17. Aurinia Pharmaceuticals Inc has a fifty-two week low of $7.28 and a fifty-two week high of $16.88.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, May 7th. The biotechnology company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.18 by $0.07. The firm had revenue of $77.71 million during the quarter, compared to analysts’ expectations of $76.98 million. Aurinia Pharmaceuticals had a return on equity of 26.62% and a net margin of 99.97%. As a group, equities analysts predict that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current fiscal year.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang purchased 516,439 shares of the stock in a transaction dated Friday, February 27th. The stock was bought at an average price of $13.99 per share, with a total value of $7,224,981.61. Following the acquisition, the director owned 11,845,939 shares of the company’s stock, valued at approximately $165,724,686.61. This represents a 4.56% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 12.20% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday. Two analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Aurinia Pharmaceuticals has an average rating of “Hold” and a consensus price target of $17.25.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.